• Creative Proteomics provides N-terminal sequence analysis by both Edman and Mass spectrometry of therapeutic proteins, monoclonal antibodies and protein vaccines. N-terminal Sequencing https://www.creative-proteomics.com/services/sequence-analysis-of-peptides-or-proteins.htm
    Creative Proteomics provides N-terminal sequence analysis by both Edman and Mass spectrometry of therapeutic proteins, monoclonal antibodies and protein vaccines. N-terminal Sequencing https://www.creative-proteomics.com/services/sequence-analysis-of-peptides-or-proteins.htm
    WWW.CREATIVE-PROTEOMICS.COM
    Sequence Analysis of Peptides or Proteins
    Creative Proteomics offers protein sequence analysis that reveals the pattern in which protein cells are formed and the amoni acids are placed within. This method is used to identify the modified residues or crosslinked sites in proteins.
    0 Comments 0 Shares 55 Views 0 Reviews
  • Conjugation is a process in which two molecules/polymers or biomolecules/biopolymers are covalently linked together. Studies have shown that antibody molecules have many functional groups suitable for modification or conjugation purposes. Antibody-oligonucleotide conjugates or AOC belong to a class of chimeric molecules that bind to two important families of biomolecules: monoclonal antibodies and oligonucleotides. Cross-linked oligonucleotides-antibodies can be achieved by lysine and N-terminal groups. The combination of the excellent targeting ability of monoclonal antibodies and many functional forms of oligonucleotides has achieved fruitful results in various applications of AOC, including imaging, detection and targeted therapy. antibody aso conjugate https://bioconjugation.bocsci.com/services/antibody-oligonucleotide-conjugation.html
    Conjugation is a process in which two molecules/polymers or biomolecules/biopolymers are covalently linked together. Studies have shown that antibody molecules have many functional groups suitable for modification or conjugation purposes. Antibody-oligonucleotide conjugates or AOC belong to a class of chimeric molecules that bind to two important families of biomolecules: monoclonal antibodies and oligonucleotides. Cross-linked oligonucleotides-antibodies can be achieved by lysine and N-terminal groups. The combination of the excellent targeting ability of monoclonal antibodies and many functional forms of oligonucleotides has achieved fruitful results in various applications of AOC, including imaging, detection and targeted therapy. antibody aso conjugate https://bioconjugation.bocsci.com/services/antibody-oligonucleotide-conjugation.html
    BIOCONJUGATION.BOCSCI.COM
    Antibody Oligonucleotide Conjugation - Bioconjugation / BOC Sciences
    With a wealth of experience and advanced technology, we can now provide you with the specific antibody-oligonucleotide conjugation.
    0 Comments 0 Shares 59 Views 0 Reviews
  • Antibody drug conjugate (ADC) is a monoclonal antibody that binds to bioactive drugs through chemical conjugates with unstable bonds. By combining the unique targeting of mAb and the cancer-killing ability of cytotoxic drugs, ADC can sensitively distinguish healthy tissues from diseased tissues. This technically challenging therapy combines innovations in biotechnology and chemistry to form a new class of highly effective biopharmaceutical drugs. The efficacy of antibody drug conjugates is achieved by covalently linking monoclonal antibodies that recognize specific tumor-associated antigens with cytotoxic agents through stable junctions. The reagent induces cell death only after it is internalized by mAb and released into specific cancer cells. Compared with standard chemotherapy and cancer biological agents, antibody drug couplings limit systemic exposure and improve drug tolerance-passing the lethal payload directly to the target tumor cells without affecting healthy tissue. adc antibody drug conjugate https://bioconjugation.bocsci.com/services/antibody-drug-conjugation.html
    Antibody drug conjugate (ADC) is a monoclonal antibody that binds to bioactive drugs through chemical conjugates with unstable bonds. By combining the unique targeting of mAb and the cancer-killing ability of cytotoxic drugs, ADC can sensitively distinguish healthy tissues from diseased tissues. This technically challenging therapy combines innovations in biotechnology and chemistry to form a new class of highly effective biopharmaceutical drugs. The efficacy of antibody drug conjugates is achieved by covalently linking monoclonal antibodies that recognize specific tumor-associated antigens with cytotoxic agents through stable junctions. The reagent induces cell death only after it is internalized by mAb and released into specific cancer cells. Compared with standard chemotherapy and cancer biological agents, antibody drug couplings limit systemic exposure and improve drug tolerance-passing the lethal payload directly to the target tumor cells without affecting healthy tissue. adc antibody drug conjugate https://bioconjugation.bocsci.com/services/antibody-drug-conjugation.html
    BIOCONJUGATION.BOCSCI.COM
    Antibody-Drug Conjugation - Bioconjugation / BOC Sciences
    As a leading service provider focused on drug development, BOC Sciences's scientific team has been supporting customers at the forefront of antibody drug conjugate development and will apply first-hand expertise to your unique project needs.
    0 Comments 0 Shares 304 Views 0 Reviews